θ°©£¨GC£©ÊÇÈ«ÇòµÚÎå´ó¶ñÐÔÖ×Áö£¬Ã¿ÄêÓÐÁè¼Ý100Íòз¢²¡Àý¡£×î½üµÄÒ»ÏîÑо¿ÏÔʾ£¬ÄêÇáÈ˵ÄGC·¢²¡ÂÊÏÔÖøÔö¼Ó¡£GCͨ³£Óë²»Á¼½á¾ÖÓйأ¬ËüÊÇÄ¿Ç°°©Ö¢Ïà¹ØËÀÍöµÄµÚÈý´ó³£¼ûÔÒò¡£×÷ΪÒì¹¹µÄ¡¢ÅÓ´óµÄºÍ¶àÒòËؼ²²¡£»GCµÄ»¼Õ߼䡢»¼ÕßÄÚºÍÖ×ÁöÄÚÒìÖÊÐÔÊǾö¶¨ÖÎÁÆ·½°¸µÄÒªº¦ÕÏ°¡£ÀýÈ磬ÓÉÓÚÎ÷·½ºÍ¶«·½¹ú¼ÒÖ×ÁöµÄÉúÎïѧ²îÒ죬ºÜÄÑÈ·¶¨¹ú¼Ê¹«Èϵij߶ÈÖÎÁÆ¡£ÔÚÑÇÖÞ£¬ÊÖÊõ¼Ó¸¨Öú»¯ÁÆÊǸü³£¼ûµÄÑ¡Ôñ£¬¶øи¨Öú»¯ÁÆ¡¢·ÅÁÆÔòÔÚÑÇÖÞÒÔÍâµØÓò³ÉΪÊ×Ñ¡¡£ÏÖÔÚÈËÃÇÆÕ±éÈÏΪ£¬×î¼ÑÖÎÁÆÒªÁìÈ¡¾öÓÚGC»¼ÕߵĻùÒò×éºÍ·Ö×ÓÉúÎïѧÌØÕ÷¡£
΢ÎÀÐǸ߲»Îȶ¨ÐÔ£¨MSI-H£©×Ô´Ó±»Åú×¼×÷Ϊ·º°©ÖÖÃâÒßÖÎÁÆÉúÎï±êÖ¾ÎïÒÔÀ´£¬Êܵ½ÁËÈËÃǵĹ㷺¹Ø×¢¡£È»¶ø£¬ÓÉÓÚÉúÎïѧµÄÅÓ´óÐÔ£¬MSI-Hθ°©£¨GC£©µÄÌØÕ÷ÔÚÎÄÏ×±¨µÀÖв¢·×ÆçÖ¡£±¾ÎĵÄÈ«¾°ÃèÊö¿ÉÄÜÓÐÖúÓÚÉè¼Æ»ò½âÊÍÁÙ´²ÊÔÑ飬ΪҩÎ￪·¢Ìṩ²Î¿¼£¬²¢¿É³ÉΪÆð²ÝÁÙ´²Êµ¼ùÖ¸ÒýµÄÔö²¹ÐÅÏ¢¡£
ÒªÁìѧ
½ØÖ¹µ½2022 Äê 12 Ô£¬Ê¹ÓÃÒªº¦×֓΢ÎÀÐÇ”¡¢“´íÅäÐÞ¸´”¡¢“¸´ÖÆ´íÎó“ºÍ”θ°©”ÔÚEmbase¡¢PubMed ºÍ Cochrane Êý¾Ý¿âÖнøÐÐÁËϵͳÐÔ¼ìË÷£¬Í¨¹ý¶ÔÀ´×Ô134¸öÐÐÁеÄ43246Ãû»¼Õß½øÐÐ×ÛºÏÆÀ¹À£¬ÓÃÒÔÃèÊöMSI-Hθ°©»¼ÕߵĻ¼²¡ÂÊ¡¢·çÏÕÒòËØ¡¢ÁÙ´²²¡Àíѧ/·Ö×ÓÉúÎïѧÌØÕ÷¼°ÁÙ´²½á¹û¡£
Èë×é³ß¶ÈΪ£º
£¨1£©¹ØÓÚÈËÀàθ°©µÄÔ´´ÎÄÕ£¬°üÂ޻عËÐÔºÍÇ°Õ°ÐÔÐÐÁÐÑо¿¡£
£¨2£©ÒÔÓ¢ÎijöÊé¡£
£¨3£©ÓпÉÓÃMSI-H GCµÄ·¢²¡ÂÊ¡¢·çÏÕÒòËØ¡¢ÁÙ´²²¡ÀíÌØÕ÷¡¢·Ö×ÓÉúÎï±êÖ¾Îï»òÁÙ´²½á¹ûÊý¾ÝµÄÑо¿¡£
Åųý³ß¶ÈΪ£º
£¨1£©¹ØÓÚ¸ÃÖ÷ÌâµÄÆäËûÑо¿£¬°üÂÞÁÙ´²Ç°ÂÛÎÄ£¬×ÛÊöÎÄÕ£¬ºóÀ´·¢±íÊý¾ÝµÄÔçÆÚ°æ±¾¡£
£¨2£©¶ù¿ÆÈËȺÑо¿¡£
£¨3£©Êý¾ÝÀ´Ô´Î´·¢±íµÄÑо¿¡£
½á ÂÛ
GC»¼ÕßÖÐMSI-HµÄ±ÈÀýΪ14.5%£¨95%CI£¬13.3%-15.8%£©¡£MSI-H GC»¼ÕßѬȾEB²¡¶¾µÄ¿ÉÄÜÐÔ½ÏС¡£MSI-H GC¸ß·¢²¡ÂʵķçÏÕÒòËØÓëÅ®ÐÔ¡¢¸ßÁä¡¢·¢²¡²¿Î»¡¢×é֯ѧÑÇÐÍ£¬ºÍ¼²²¡½ø³ÌÓйء£´ËÍ⣬MSI-H GC »¼ÕßЯ´ø¸ü¶àµÄKRAS Í»±ä¡¢²¢ÌåÏÖ³ö¸ü¶àµÄPD-L1ÑôÐÔ¡¢CD8 ¹ý±í´ïºÍ¸ü¸ßµÄ TMB£¬µ«½ÏÉÙ·ºÆð HER2 ÑôÐÔºÍЯ´øTP53Í»±ä¡£µ±½ÓÄÉͨÀý¼ÆıÖÎÁÆʱ£¬MSI-H»¼Õߣ¨70.3%£©ºÍMSI-L/MSS»¼Õߣ¨43.7%£©µÄ5ÄêÉú´æÂÊÏÔÖø²îÒì £¨P<0.001£©¡£MSI-H GC»¼ÕßÔÚ×ÜÉú´æÆںͿ͹ۻº½â·½Ãæ´ÓÃâÒßÖÎÁÆÖеĻñÒæ¸ü´ó¡£ÓÉÓÚ MSI-H GC µÄ»¼²¡ÂÊÏà¶Ô½Ï¸ß£¬¶øÇÒ¾ßÓÐÃ÷ÏÔµÄÁÙ´²²¡ÀíѧºÍ·Ö×ÓÉúÎïѧÌØÕ÷£¬Òò´Ë MSI ¼ì²âÓ¦Ôڳ߶ÈÕï¶Ï»î¶¯ÆÚ¼ä½øÐС£´ËÍ⣬ÓÉÓÚMSI-HÖ×Áö»¼Õßͨ³£ÔÚÔçÆÚ±»Õï¶Ï³öÀ´²¢¾ßÓÐÁ¼ºÃµÄÁÙ´²½á¹û£¬ÔÚÁÙ´²Êµ¼ùÖпÉÒÔ¿¼ÂDz»Ì«»ý¼«µÄÖÎÁƼÆı¡£
½á¹û 1£ºÓëÎ÷·½¹ú¼ÒÏà±È£¬MSI-H GCµÄ±ÈÀýÔÚ¶«ÑǵØÓòÏÔÖø½µµÍ¡£
MSI-H GC»¼ÕßµÄ×ÜÌå±ÈÀýΪ14.5%£¨95%CI, 13.3%-15.8%£©£¬×î¸ßÔÚÄÏÃÀÖÞ£¨21.8%; 95%CI, 17.1%-26.9%£©£¬Æä´ÎÊDZ±ÃÀ£¨17.9%; 5.9%-34.7%£©£¬Å·ÖÞ£¨16.8%; 14.1%-19.8%£©ºÍÑÇÖÞ£¨13.7%; 12.4%-15.1%£©£¨ÈçÏÂͼ£©¡£
½á¹û 2£º½ÒʾÁËMSI-H GCDZÔÚµÄÁ÷Ðв¡Ñ§ÒÔ¼°¿ÉÄÜÔö¼Ó·¢²¡ÂʵÄΣÏÕÒòËØ¡£
MSI-HÊÇÓë¼Ò×åÒ׸ÐÐÔ£¨p=0.87£©¡¢ÓÄÃÅÂݸ˾úѬȾ£¨p=0.83£©¡¢ÎüÑÌ£¨p=0.07£©ÒÔ¼°Òû¾ÆÁ¿£¨P=0.85£©Î޹صĶÀÁ¢ÒòËØ¡£Í¬Ê±£¬ÓëMSI-L/MSS»¼ÕßÏà±È£¬MSI-H GC»¼Õß·¢ÉúEBVѬȾµÄ¿ÉÄÜÐÔ¸üµÍ£¨OR£¬0.43;95%CI£¬0.21-0.86;p=0.02£©¡£
MSI-H GCµÄ·¢²¡ÂÊÔÚÅ®ÐÔ(>65Ëꣻ1.80;1.41-2.32;p<0.001)ºÍÀÏÄêÈË(>65Ëꣻ1.80;1.41-2.32;p<0.001)Öнϸߡ£MSI-HÖ×Áö¸ü¿ÉÄÜ·¢ÉúÔÚθϲ¿(OR,2.17;95% CI,1.85-2.53;p<0.001)£¬¶ø²»ÊÇÔÚÉϲ¿(0.55;0.43-0.71;p<0.001)ºÍÖв¿(0.63;0.56-0.71;p<0.001)¡£ÓëMSI-L/MSS GCÏà±È£¬¸ü¶àµÄMSI-HÖ×Áö±»¹éÀàΪLauren³¦ÐÍ(OR,2.02;95% CI,1.74-2.34;p<0.001)£¬ÃÖÂþÐͽÏÉÙ(0.45;0.39-0.52;p<0.001)¡£Æ¾¾ÝWHO·ÖÀ࣬MSI-HÖ×Áö¸ü¿ÉÄܱ»¼ø¶¨Îª¹Ü×´ÑÇÐÍ(OR,1.22;95% CI,1.11-1.34;p<0.001)ºÍð¤ÒºÑÇÐÍ(2.02;1.22-3.35;p=0.01)£¬µ«Ó¡½äϸ°ûÑÇÐÍ(0.28;0.18-0.45;p<0.001)ºÍµÍ·Ö»¯ÑÇÐÍ(0.79;0.64-0.97;p=0.02)½ÏÉÙ¡£´ËÍ⣬MSI-HÖ×Áö¸ü³£ÔÚ¼²²¡µÄÔçÆڽ׶α»Õï¶Ï(OR,1.26;95% CI,1.07-1.48;p=0.01)¡£
½á¹û 3£ºÍ¨¹ýһϵÁÐÁÙ´²²¡ÀíÌØÕ÷ºÍ·Ö×ÓÉúÎï±êÖ¾Îï¼ì²é£¬Ö¤ÊµÁËMSI-H GC¾ßÓÐÌض¨µÄÒÅ´«Æס£
MSI-HÓë½Ï¸ßµÄKRASÍ»±ä(OR, 5.56;95% ci, 3.76 -8.23;p < 0.001)±ÈÀý¡¢PD-L1ÑôÐÔÂÊ(4.04;2.94 - 5.56;p < 0.001), CD8³¬±í´ï(2.34;1.28 - 4.27;P =0.006)¡¢¸ßTMB (TMB>10Í»±äÌå/Mb;p<0.001)Ïà¹Ø£¬¶øÓëHER2ÑôÐÔÂÊ (0.33;0.19 -0.55;p<0.001)ºÍTP53Í»±äÂÊ(0.39;0.30 -0.50;p < 0.001)Î޹ء£HER2ÑôÐÔºÍMSI-HÖ×ÁöÌåÏÖ³ö¸ºÏà¹ØµÄ¹Øϵ£¬²»µ½3%µÄMSI-H GCΪHER2ÑôÐÔ£»Í¬Ê±TP53ÔÚMSI-H²¡ÀýÖÐÒµºÜÉÙ·¢ÏÖ¡£MSI-Hθ°©¾ßÓиü¸ßµÄPD-L1¡¢CD8+ TILºÍTMBµÄ±í´ï¡£ÓÉÓÚPD-L1±í´ïµÄÔ¤ºó¼ÛÖµ¾ßÓÐÕùÒ飬Òò´Ë½¨ÒéÁªºÏÆÀ¹ÀMSI״̬ºÍPD-L1±í´ïÀ´Ö¸µ¼»¼ÕßÃâÒßÖÎÁƷֲ㡣EB²¡¶¾Ñ¬È¾ÁËÈ«ÊÀ½ç90%µÄÈË¿Ú²¢¿ÉÖ±½ÓÒýÆðebvÏà¹ØGC£¬µ«±¾ÎĵķÖÎöÏÔʾ£¬¼¸ºõËùÓеÄMSI-H GC¶¼ÊÇEBVÒõÐÔµÄ(~97%)¡£EBVÑôÐÔMSI-HÖ×Áö¿ÉÄÜÊôÓÚÌØÊâµÄÑÇȺ¡£
½á¹û 4£ºMSI-HÖ×Áö»¼ÕßµÄÉú´æ½á¾Ö½ÏºÃ¡£
ÔÚ40ÐÐÁÐÖÐÄÉÈëÁË17081Àý½ÓÊÜͨÀýÖÎÁƵÄGC»¼Õß¡£ÆäÖÐMSI-H»¼ÕßµÄ5ÄêÉú´æÂÊΪ70.3%£¬ÏÔÖø¸ßÓÚMSI-L/MSS»¼Õߣ¨43.7%£©£¬²îÒìÓÐͳ¼ÆѧÒâÒå(p < 0.05)¡£4ÏîIIIÆÚËæ»úÊÔÑ飬KEYNOTE-061¡¢KEYNOTE-062¡¢JAVELIN Gastric 100ºÍCheckMate-649±»ÄÉÈëÒÔÆÀ¹ÀÃâÒßÖÎÁƵÄÁÆЧ(ÈçÏÂͼ)¡£Óë³ß¶ÈÖÎÁÆÏà±È£¬ÃâÒßÖÎÁÆʹMSI-H GC»¼ÕßËÀÍö·çÏÕ½µµÍÁË68%(HR 0.32;95% CI, 0.19 ~ 0.54)£»MSI-L/MSSGC»¼Õß½µµÍÁË12%(·çÏձȣ¬0.88;95% ci, 0.79-0.99)¡£Á½¸öÑÇ×éµÄÉú´æ½á¾ÖÓÐÏÔÖø²îÒì (p½»»¥×÷ÓÃ<0.001)¡£´ó¶àMSI-Hθ°©»¼Õ߶ÔÃâÒßÖÎÁƵķ´Ó³ÓÅÓÚ»¯ÁÆ(RR, 1.55; 95% CI, 1.09-2.19;p<0.001);¶øMSI-L/MSS±ÈÀýÏàËÆθ°©»¼Õ߶ÔÃâÒßÖÎÁƺͻ¯ÁÆÓз´Ó³(RR, 0.71; 95% CI, 0.41-1.21)¡£
²Î¿¼ÎÄÏ×
Zhang Z, Huang J, Li Y, Yan H, Xie J, Wang J, Zhao B. Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer. Aging (Albany NY). 2024 Jan 12;15. doi: 10.18632/aging.205431. Epub ahead of print. PMID: 38224334.
ÔÁ¹«Íø°²±¸ 44030602000441ºÅ 